PCMT1 Is a Potential Prognostic Biomarker and Is Correlated with Immune Infiltrates in Breast Cancer

Guo, Jufang; Du, Xuelian; Li, Chaolin

doi:10.1155/2022/4434887

Cited by 9 publications

(5 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two recent studies have shown that high expression level of PCMT1 is closely associated with poor prognosis of breast cancer patients (Guo et al., 2022; Zhang et al., 2023). Moreover, silencing PCMT1 expression effectively inhibits the proliferation and invasion of breast cancer cells and promotes apoptosis of them, so PCMT1 is also considered as a potential prognostic biomarker in breast cancer (Guo et al., 2022; Zhang et al., 2023). In this study, PCMT1 was also found to be significantly up‐regulated in breast cancer tissues and MCF‐7/PR cells and was associated with poor prognosis of breast cancer patients.…”

Section: Discussionmentioning

confidence: 99%

“…It presents high expression in tumor tissues and cells and thus is considered as prognostic biomarker for the above tumors. Two recent studies have shown that high expression level of PCMT1 is closely associated with poor prognosis of breast cancer patients (Guo et al., 2022; Zhang et al., 2023). Moreover, silencing PCMT1 expression effectively inhibits the proliferation and invasion of breast cancer cells and promotes apoptosis of them, so PCMT1 is also considered as a potential prognostic biomarker in breast cancer (Guo et al., 2022; Zhang et al., 2023).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Silencing PCMT1 enhances the sensitivity of breast cancer cells to paclitaxel through the PI3K/Akt/STMN1 pathway

Zhang,

Li,

2024

Chem Biol Drug Des

View full text Add to dashboard Cite

This study aimed to investigate whether silencing Protein L‐isoaspartate (D‐aspartate) O‐methyltransferase (PCMT1) expression can enhance the sensitivity of breast cancer cells to paclitaxel and its possible mechanism. Tumor tissues and adjacent histologically normal tissues were collected from patients with breast cancer admitted to our hospital. Human normal breast epithelial cells MCF10A, human breast cancer cells MCF‐7, and paclitaxel‐resistant breast cancer cells MCF‐7/PR were purchased. MCF‐7/PR cells were further grouped into negative control (NC) group, si‐PCMT1 group (transfected with si‐PCMT1), 740Y‐P group (treated with 740Y‐P, an activator of phosphatidylinositol 3‐kinase (PI3K)/ v‐Akt Murine Thymoma Viral Oncogene (AKT) signaling pathway), and si‐PCMT1 + 740Y‐P group (transfected with si‐PCMT1 and then treated with 740Y‐P). The expression level of PCMT1 in tissues and cells was detected by quantitative real‐time polymerase chain reaction (qRT‐PCR). Western blot analysis was used to detect the protein expression level of PCMT1 in tissues and cells as well as the protein level of p‐PI3K, PI3K, p‐Akt, Akt, and Stathmin1 (STMN1) in cells. 3‐(4,5)‐dimethylthiahiazo(‐z‐y1)‐3,5‐di‐phenytetrazoliumromide (MTT) and colony formation assays were used to determine cell viability, scratch assay was used to assess the migration ability of cells, and Transwell assay was used to assess the invasion ability of cells. The expression of PCMT1 was remarkably up‐regulated in breast cancer tissues and MCF‐7/PR cells. Silencing PCMT1 expression significantly inhibited the proliferation, migration, and invasion of MCF‐7/PR cells, and alleviated the resistance of cancer cells to paclitaxel. Additionally, silencing PCMT1 expression also inhibited the activation of PI3K/Akt/STMN1 pathway in MCF‐7/PR cells, while activating PI3K/Akt/STMN1 pathway significantly reversed the effect of silencing PCMT1 expression on MCF‐7/PR cells. PCMT1 is highly expressed in breast cancer tissues and MCF‐7/PR cells, and silencing PCMT1 expression can not only inhibit the development of breast cancer but also enhance paclitaxel sensitivity. Its mechanism of action may be achieved by inhibiting PI3K/Akt/STMN1 signaling.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Silencing PCMT1 enhances the sensitivity of breast cancer cells to paclitaxel through the PI3K/Akt/STMN1 pathway

Zhang,

Li,

2024

Chem Biol Drug Des

View full text Add to dashboard Cite

show abstract

“…PCMT1 is a member of the type 2 class of protein carboxyl methyltransferase enzymes. Studies show an association of elevated PCMT1 levels with various cancer types like breast cancer [ 69 , 70 , 71 , 72 , 73 , 74 ]. Another study constructing a genetic network for rheumatoid arthritis by evaluating genome-wide SNPs showed that PCMT1 is within the 41 identified significant SNPs, which is relevant to rheumatoid arthritis [ 75 ].…”

Section: Discussionmentioning

confidence: 99%

Patients with Systemic Juvenile Idiopathic Arthritis (SJIA) Show Differences in Autoantibody Signatures Based on Disease Activity

Krainer,

Hendling,

Siebenhandl

et al. 2023

Biomolecules

View full text Add to dashboard Cite

Systemic juvenile idiopathic arthritis (SJIA) is a severe rheumatic disease in children. It is a subgroup of juvenile idiopathic arthritis (JIA; MIM #604302), which is the most common rheumatic disease in children. The diagnosis of SJIA often comes with a significant delay, and the classification between autoinflammatory and autoimmune disease is still discussed. In this study, we analyzed the immunological responses of patients with SJIA, using human proteome arrays presenting immobilized recombinantly expressed human proteins, to analyze the involvement of autoantibodies in SJIA. Results from group comparisons show several differentially reactive antigens involved in inflammatory processes. Intriguingly, many of the identified antigens had a high reactivity against proteins involved in the NF-κB pathway, and it is also notable that many of the detected DIRAGs are described as dysregulated in rheumatoid arthritis. Our data highlight novel proteins and pathways potentially dysregulated in SJIA and offer a unique approach to unraveling the underlying disease pathogenesis in this chronic arthropathy.

show abstract

“…For example, PCMT1 expression was signi cantly higher in hepatocellular carcinoma, bladder cancer, advanced-stage lung adenocarcinoma and metastatic ovarian cancer, and higher PCMT1 expression predicted poor prognosis of above malignant tumors [6,7,11,23]. Up to now, although it has showed that PCMT1 mRNA was highly expressed in BC, and the survival of BC patient with higher expression of PCMT1 was signi cantly poorer than those with lower expression [8][9][10]. However, no clinical information regarding the relationship between PCMT1 protein expression and clinicopathological characteristics of BC patients has been reported.…”

Section: Discussionmentioning

confidence: 99%

“…Previous studies indicated that higher PCMT1 protein expression is not only an unfavorable prognostic biomarker of surgically removed lung adenocarcinoma but also a predictive biomarker for poor prognosis of bladder cancer [6,7]. In addition, there are some researches showed that the outcome of BC patients with higher expression of PCMT1 gene was signi cantly poorer than those with lower expression [8][9][10].…”

Section: Introductionmentioning

confidence: 99%

PCMT1 has Potential Prognostic Value and Promotes Cell Growth and Motility in Breast Cancer

Lin

Zhuang

et al. 2022

Preprint

View full text Add to dashboard Cite

Breast cancer (BC) is one of the frequently diagnosed cancers, and the leading cause of cancer-related death among women worldwide. The roles of protein L-isoaspartate (D-aspartate) O-methyltransferase (PCMT1) in human cancer have been exploring, but the clinical significance and biological function of PCMT1 in BC are not yet clear. In this study, based on the TCGA-BRCA data set, the results showed that high expression of PCMT1 gene was significantly correlated with shorter overall survival (OS), disease specific survival (DSS) and progress free suvival (PFS) of BC patients. Utilizing the immunohistochemical assay, we found that PCMT1 protein was located in the cytoplasm of BC cells, and PCMT1 expression was only obviously correlated with progesterone receptor expression of patients (p < 0.05). Survival analysis showed that PCMT1 protein high-expression was an independent unfavorable prognostic factor for BC patients. The in vitro experiments revealed that PCMT1 could regulate growth, migration and invasion capacity of MCF-7 cell, and modulate the expression of AKT/GSK3β/mTOR signaling pathway, EMT and cell cycle-associated protein. In conclusion, PCMT1 was a potential unfavorable prognostic biomarker for BC patient and might influence the AKT/GSK3β/mTOR signaling pathway to regulate the growth and motility of MCF-7 cell.

show abstract

PCMT1 Is a Potential Prognostic Biomarker and Is Correlated with Immune Infiltrates in Breast Cancer

Cited by 9 publications

References 49 publications

Silencing PCMT1 enhances the sensitivity of breast cancer cells to paclitaxel through the PI3K/Akt/STMN1 pathway

Silencing PCMT1 enhances the sensitivity of breast cancer cells to paclitaxel through the PI3K/Akt/STMN1 pathway

Patients with Systemic Juvenile Idiopathic Arthritis (SJIA) Show Differences in Autoantibody Signatures Based on Disease Activity

PCMT1 has Potential Prognostic Value and Promotes Cell Growth and Motility in Breast Cancer

Contact Info

Product

Resources

About